Imunon Inc. Common Stock (IMNN)

About IMNN

Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase for glioblastoma. It is…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

20

Website

imunon.com/

Fundamentals

1-day range

$1.6$1.65

Market cap

$6.64M

P/E (trailing)

—

P/E (forward)

-0.93

EPS (trailing)

$-5.74

Dividend yield

—

Beta

2.01

Avg. volume

126.1K

Forecasts

5 analyst ratings

Imunon Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• IMNN

  Imunon Inc. Common Stock

  $1.58

  ▼ 1.25%
  Market cap $6.64MP/E —
  $1.47$6.39
• ALZN

  Alzamend Neuro Inc. Common Stock

  $1.66

  ▼ 0.30%
  Market cap $6.42MP/E —
  $0.84$2.68
• PCSA

  Processa Pharmaceuticals Inc. Common Stock

  $2.07

  ▼ 1.90%
  Market cap $7.09MP/E —
  $1.67$14.24
• ACXP

  Acurx Pharmaceuticals Inc. Common Stock

  $1.45

  ▼ 1.03%
  Market cap $6.15MP/E —
  $1.31$8.34
• TRAW

  Traws Pharma Inc. Common Stock

  $0.59

  ▲ 0.00%
  Market cap $7.18MP/E —
  $0.4301$3.27
• HCWB

  HCW Biologics Inc. Common Stock

  $3.39

  ▲ 6.94%
  Market cap $6.06MP/E —
  $1.5$38.16
• APUS

  Apimeds Pharmaceuticals US Inc. Common Stock

  $3.87

  ▼ 1.28%
  Market cap $7.32MP/E —
  $3.39$403.1

P/E shows — for peers not currently carrying a live signal of their own.

Institutional Ownership

March 31, 2026

Total shares held

490.3K

Total value held

$1.55M

Institutional holders

18